Case Report

Treatment response of sofosbuvir in HCV virus/ Helicobacter pylori co-infected patient a case report


  • Braira Wahid

Received Date: 11.06.2019 Accepted Date: 01.10.2019 Gulhane Med J 2019;61(4):189-191

Newly developed direct-acting anti-viral drugs act as a major breakthrough in the area of HCV therapeutics. Accumulating evidence suggest that more than 99% patients achieve sustained virological response after receiving sofosbuvir-based therapy. However, we observed the first case of DAA treatment failure in HCV patient who was co-infected with H. Pylori.

Keywords: DAA drugs, HCV, H. pylori, sofosbuvir, relapse.